Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
9,351,765
-
Share change
-
-791,641
-
Total reported value
-
$27,595,077
-
Put/Call ratio
-
404%
-
Price per share
-
$2.95
-
Number of holders
-
72
-
Value change
-
-$1,941,847
-
Number of buys
-
33
-
Number of sells
-
49
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q4 2023
As of 31 Dec 2023,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,351,765 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., VANGUARD GROUP INC, AMERIPRISE FINANCIAL INC, ADAGE CAPITAL PARTNERS GP, L.L.C., GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, Beacon Pointe Advisors, LLC, NORTHERN TRUST CORP, and MORGAN STANLEY.
This page lists
72
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.